Literature DB >> 21161157

[Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].

J Müller1, A J Schrader, F Jentzmik, M Schrader.   

Abstract

BACKGROUND: Meta-analysis evaluating the accuracy and sensitivity of FDG (2-[(18)F]-fluoro-2-deoxy-D-glucose) positron emission tomography (PET) to predict viable residual tumours in patients with metastatic seminoma.
MATERIAL AND METHODS: Altogether 5 studies with 130 patients were identified. Both FDG PET and the size of the residual lesions on conventional computed tomography (CT; lesions either ≤ or > 3 cm) were correlated with the presence or absence of viable residual tumour.
RESULTS: The specificity (92 vs 59%), sensitivity (72 vs 63%), positive (70 vs 28%) and negative (93 vs 86%) predictive value of FDG PET were superior to data obtained by assessing residual tumour size (either ≤ or > 3 cm) applying CT scans alone.
CONCLUSION: In view of the data currently available, FDG PET seems to be a clinically useful predictor of viable tumour in post-chemotherapy residuals of pure seminoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21161157     DOI: 10.1007/s00120-010-2469-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  27 in total

1.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

2.  Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?

Authors:  H W Herr
Journal:  Br J Urol       Date:  1997-10

3.  Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.

Authors:  E W Steyerberg; A Gerl; S D Fossá; D T Sleijfer; R de Wit; W J Kirkels; N Schmeller; C Clemm; J D Habbema; H J Keizer
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

4.  Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.

Authors:  S D Fosså; R T Oliver; S P Stenning; A Horwich; P Wilkinson; G Read; G M Mead; J T Roberts; G Rustin; M H Cullen; S B Kaye; S J Harland; P Cook
Journal:  Eur J Cancer       Date:  1997-08       Impact factor: 9.162

5.  Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group.

Authors:  Peter Albers; Lothar Weissbach; Susanne Krege; Sabine Kliesch; Michael Hartmann; Axel Heidenreich; Peter Walz; Markus Kuczyk; Rolf Fimmers
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

6.  Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?

Authors:  Ashraf A Mosharafa; Richard S Foster; Bradley C Leibovich; Richard Bihrle; Cynthia Johnson; John P Donohue
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

7.  Trends in the incidence of testicular germ cell tumors in the United States.

Authors:  Katherine A McGlynn; Susan S Devesa; Alice J Sigurdson; Linda M Brown; Lilian Tsao; Robert E Tarone
Journal:  Cancer       Date:  2003-01-01       Impact factor: 6.860

8.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz-Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

Review 9.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

10.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.

Authors:  Maria De Santis; Alexander Becherer; Carsten Bokemeyer; Franz Stoiber; Karin Oechsle; Franz Sellner; Alois Lang; Kurt Kletter; Bernhard M Dohmen; Christian Dittrich; Jörg Pont
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  11 in total

Review 1.  Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.

Authors:  Mehmet Asim Bilen; Houssam Hariri; Chady Leon; Charles C Guo; Deborah A Kuban; Louis L Pisters; Shi-Ming Tu
Journal:  Clin Genitourin Cancer       Date:  2014-02-28       Impact factor: 2.872

Review 2.  Surgical removal of retroperitoneal tumors after chemotherapy treated testicular tumors.

Authors:  Allen Sim; Stefan Aufderklamm; Omar Halalsheh; Tilman Todenhöfer; Christian Schwentner
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

Review 3.  [Value of positron emission tomography in urological neoplasms: more form than substance?].

Authors:  J Müller; M Schrader; A J Schrader; M Höpfner; F Zengerling
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

Review 4.  Update on advances in molecular PET in urological oncology.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Kazuhito Fukushima; Ryogo Minamimoto; Takao Kamai; Hossein Jadvar
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

Review 5.  [Diagnostics and treatment of seminomatous germ cell tumors].

Authors:  F Zengerling; J Müller; S Krege; M Schrader
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

6.  Appropriateness criteria of FDG PET/CT in oncology.

Authors:  Archi Agrawal; Venkatesh Rangarajan
Journal:  Indian J Radiol Imaging       Date:  2015 Apr-Jun

7.  Primary mediastinal seminoma; resistance and relapse: An aggressive entity.

Authors:  Ankita Nachankar; Rahul Krishnatry; Amit Joshi; Vanita Noronha; Jai Prakash Agarwal
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

Review 8.  Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.

Authors:  Giorgio Treglia; Ramin Sadeghi; Salvatore Annunziata; Carmelo Caldarella; Francesco Bertagna; Luca Giovanella
Journal:  Biomed Res Int       Date:  2014-05-15       Impact factor: 3.411

Review 9.  PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.

Authors:  Abdul Razik; Chandan Jyoti Das; Sanjay Sharma
Journal:  Indian J Urol       Date:  2018 Jan-Mar

Review 10.  Imaging of the scrotum: beyond sonography.

Authors:  Gian Carlo Parenti; Francesco Feletti; Aldo Carnevale; Licia Uccelli; Melchiore Giganti
Journal:  Insights Imaging       Date:  2018-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.